REVIEW ON FORMULATION AND EVALUATION OF SOLID LIPID NANOPARTICLES FOR VAGINAL APPLICATION
DOI:
https://doi.org/10.22159/ijpps.2022v14i1.42595Keywords:
Vaginal drug delivery, Drug absorption, Low Permeability, Factors affecting, Vaginal dosage forms, Solid lipid nanoparticles, Drug releaseAbstract
Vaginal drug administration can improve prophylaxis and treatment of many conditions affecting the female reproductive tract, which includes fungal and bacterial infections, sexually transmitted diseases and cancer also. This is the best route for the administration of proteins, peptides, and also other therapeutic drugs like macro-molecules. For the administration of drugs like contraceptives, steroids, metronidazole, anti-retroviral, vaginal drug delivery is the most preferable route. However, achieving sufficient drug concentration in the vagina can be challenging because of its low permeability. The benefits of the vaginal drug delivery system are it increases the bioavailability, least systemic side effects; easiness of use and self-medication is possible. However vaginal drug delivery system is considered as a less effective route because of the unfortunate absorption of drugs across the vaginal epithelium. The traditional commercial preparations, such as creams, foams, gels, irrigations and tablets, are known to reside in the vaginal cavity for a relatively short period of time owing to the self-cleaning action of the vaginal tract and often require multiple daily doses to ensure the desired therapeutic effect. With the rapidly developing field of nanotechnology, the use of specifically designed carrier systems such as Nanoparticle-based drug delivery has been proven an excellent choice for vaginal application to overcome the challenges associated with the low permeability.
Downloads
References
Okada H, Yamazaki I, Ogawa Y, Hirai S, Yashiki T, Mima H. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement. J Pharm Sci. 1982;71(12):1367-71. doi: 10.1002/jps.2600711214, PMID 6818337.
Vermani K, Garg S, Zaneveld LJD. Assemblies for in vitro measurement of bioadhesive strength and retention characteristics in the simulated vaginal environment. Drug Dev Ind Pharm. 2002;28(9):1133-46. doi: 10.1081/ddc-120014580, PMID 12455472.
Richardson JL, Armstrong TI. Vaginal delivery of calcitonin by hyaluronic acid Formulations, bioadhesive Drug Delivery Systems: fundamentals, Novel Approaches and development; 1999. p. 563-99.
Hussain Z, Rahim MA, Jan N, Shah H, Rawas Qalaji M, Khan S, et al. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: improved pharmacokinetics, cell internalization and anticancer efficacy. J Control Release. 2021;335:130-57. doi: 10.1016/j.jconrel.2021.05.018. PMID 34015400.
Richardson JL, Illum L. (D) Routes of delivery: case studies. Adv Drug Deliv Rev. 1992;8(2-3):341-66. doi: 10.1016/0169-409X(92)90008-E.
Sjöberg I, Cajander S, Rylander E. Morphometric characteristics of the vaginal epithelium during the menstrual cycle. Gynecol Obstet Invest. 1988;26(2):136-44. doi: 10.1159/000293685, PMID 2851505.
Deshpande AA, Rhodes CT, Danish M. Intravaginal drug delivery. Drug Dev Ind Pharm. 1992;18(11-12):1225-79. doi: 10.3109/03639049209046329.
https://www.pinterest.com/pin/472948398370379766/. [Last accessed on 28 May 2021]
Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology 1985;152:247-51.
Sobel JD. Pathophysiology of vulvovaginal candidiasis. J Reprod Med. 1989;34(8);Suppl:572-9; discussion 579. PMID 2677361.
https://www.limamemorial.org/health-library/HIE%20Multimedia-TextOnly/1/001511. [Last accessed on 28 May 2021]
Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology. 1985;152:247-51.
Eschenbach DA, Hillier SL. Advances in diagnostic testing for vaginitis and cervicitis. J Reprod Med. 1989;34(8);Suppl:555-64; discussion 564. PMID 2677360.
Ramjee GA, Kamali A, Rees H, Crook AM, Gafos M. Pro2000 vaginal gel for prevention of HIV-1 infection (Microbicides development programme 301): A phase 3, randomised, double-blind, parallel-group trial. 2010;376:1329-37. The Lancet 376(9749):1329-37. doi: 10.1016/S0140-6736(10)61086-0.
Alam AM, Ahmad AF, Khan IJ. Effect of hydrophilic swellable polymers on dissolution enhancement of carbamazepine solid dispersions studied using response surface methodology. APPS PharmSciTech 2007;8:E1-8.
https://www.freepik.com/premium-photo/white-suppositories-anal-vaginal-use-blue-background-medical-candles-treatment-candida-thrush-hemorrhoids-inflammation-fever-effective-drug-timely-treatment-diseases_6828042.Htm. [Last accessed on 28 May 2021]
Lamont RF, Jones BM, Mandal D, Hay PE, Sheehan M. The efficacy of vaginal clindamycin for the treatment of abnormal genital tract flora in pregnancy. Infect Dis Obstet Gynecol. 2003;11(4):181-9. doi: 10.1080/10647440300025519, PMID 15108863.
https://farmaciajireh.com/products/clotrimazole-1-cream-w-appl-7-day-45 gm. [Last accessed on 02 Dec 2021].
Dezarnaulds G, Fraser IS. Vaginal ring delivery of hormone replacement therapy- a review. Expert Opin Pharmacother. 2003;4(2):201-12. doi: 10.1517/14656566.4.2.201, PMID 12562310.
Acarturk F, Parlatan ZI, Saracoglu OF. Comparison of vaginal aminopeptidase enzymatic activities in various animals and in humans. J Pharm Pharmacol. 2001;53(11):1499-504. doi: 10.1211/0022357011778034, PMID 11732752.
https://www.shutterstock.com/editorial/search/NuvaRing. [Last accessed on 28 May 2021].
Kanellos BTS, Russell DK, Howard PH, Partidos CR. 2000;74:215-20.
Garulli B, Kawaoka Y, Castrucci MR. Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with recombinant influenza a virus. J Virol. 2004 Jan;78(2):1020–5. doi: 10.1128/JVI.78.2.1020-1025.2004
Loxley A. Solid lipid nanoparticles for the delivery of pharmaceutical actives. Drug Deliv Technol. 2009;9Suppl 8:32.
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Ind J Pharm Sci. 2009 Jul-Aug;71(4):349-58. doi: 10.4103/0250-474X.57282.
Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3):165-96. doi: 10.1016/s0169-409x(01)00105-3, PMID 11311991.
Ekambaram P, Sathali AH, Priyanka K. Solid lipid nanoparticles. A review scientific reviews and chemical. Communication. 2012;2(1):80-102.
Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300. PMID 18019829.
Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300. PMID 18019829.
Pathak K, Keshri L, Shah M. Lipid nanocarriers: influence of lipids on product development and pharmacokinetics. Crit Rev Ther Drug Carrier Syst. 2011;28(4):357-93. doi: 10.1615/ critrevtherdrugcarriersyst.v28.i4.20, PMID 21967401.
Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery- a review of state of the art. Eur J Pharm Biopharm. 2000;50(1):161-77. doi: 10.1016/s0939-6411(00)00087-4, PMID 10840199.
Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release. 1997;48(2-3):223-36. doi: 10.1016/S0168-3659(97)00046-1.
Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300. PMID 18019829.
https://ebrary.net/61149/engineering/drug_release_solid_lipid_nanoparticles. [Last accessed on 02 Dec 2021]
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54Suppl 1:S131-55. doi: 10.1016/s0169-409x(02)00118-7, PMID 12460720.
Freitas C, Muller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm. 1999;47(2):125-32. doi: 10.1016/s0939-6411(98)00074-5, PMID 10234536.
Surender V, Deepika M. Solid lipid nanoparticles: A comprehensive review. J Chem Pharm Res. 2016;8(8):102-14.
https://www.semanticscholar.org/paper/solid-lipid-nanoparticles-of-a-water-soluble-drug%2CAgrawal/ 7b3a4287387e906d0a02e1026db105d9116427c8/figure/0. [Last accessed on 02 Dec 2021].
Anu M, Satvinder K, Singh S. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide in vitro and in vivo evaluation. J Pharm Sci. 2011;6:2366-78.
Sekar V, Rajendran K, Vallinayagam S, Deepak V, Mahadevan S. Synthesis and characterization of chitosan ascorbate nanoparticles for therapeutic inhibition for cervical cancer and their in silico modeling. J Ind Eng Chem. 2018;62:239-49. doi: 10.1016/j.jiec.2018.01.001.
Published
How to Cite
Issue
Section
Copyright (c) 2022 PRIYANKA PALLERLA
This work is licensed under a Creative Commons Attribution 4.0 International License.